Background
Evaluating patient preferences could provide additional information to supplement the traditional tests of ef®cacy in randomized, controlled trials (RCTs). Furthermore, it is very likely that greater understanding of the factors that in¯uence patient preference may ultimately provide important guidance for doctors trying to make rational choices for their patients (1) . While clinical trials examine only ef®cacy at speci®ed points in time and preference trials may provide a more real-life perspective on which medication is best for a particular individual or group of individuals.
How to de®ne preference
The most straightforward de®nition is the patient's global impression of a given treatment with respect to all its pros and cons. In preference trials, patients evaluate their individual treatment, weighing ef®cacy, onset of action, duration, reliability, tolerability, ease of use and general well being and eventually provides us with the information about how each treatment alternative is perceived. Recently performed patient preference studies in migraine demonstrate that the reasons for patient preference include best relief of migraine pain, fastest relief of pain, quickest return to normal function and few or no side-effects (1±3). Several confounding factors may affect the patient's subjective impression of the overall therapeutic properties of a given treatment (3) . Accordingly, efforts have to be made during the planning process, especially the study design, in order to make the patient preference trial as reliable as possible.
Study design
It is relatively easy to come up with a very sophisticated design of a patient preference study but it is very likely that such a trial would be both complicated and impractical to perform. In addition, the data obtained in this type of trial may not re¯ect what is happening in clinical practice. The real challenge is to ®nd the study design, which is an ideal compromise between blinding, placebo, number of attacks, number of treatment alternatives and clinical practice.
The two most common designs used in RCTs are parallel designs (between-patients) and crossover designs (within-patients) (4). In parallel design, patients are randomised to one of two or more treatment alternatives, whereas in crossover design, each patient receives both or all treatments being compared in the clinical trial. RCTs using parallel design are more robust but less sensitive in detecting potential differences between treatments. Variations in response among subgroups of the studied population may exist, but these will be averaged out in the calculation of the mean responses.
The crossover study design has the advantage that, unlike parallel studies, each patient is used as his/her own control (3). RCTs using crossover design provide data of increased sensitivity and smaller variability. The drawbacks of crossover design are that patients may be lost to follow-up during the study, and there may be carry-over effects from one treatment to the others. An additional issue includes within-patient variability. There is information to support the notion that the severity of migraine attacks varies considerably and that only about 20% have the same degree of headache severity at every attack.
Given the pros and cons of both parallel and crossover designs as outlined above, it is obvious that the crossover design has to be used when evaluating patient preferences for treatments used in the acute treatment of migraine. A complete Latin-square type cross over study where placebo is also is a choice should be considered. This design is likely to minimize the carryover effect since patients are randomly assigned to a treatment sequence. Also, an analysis by sequence of treatment as covariate would partially offset the consistency effect. Ideally, the patient preference studies should be blinded. There are, however, many practical obstacles in blinding a patient preference trial, particularly when a large number of treatments are included. Recent data suggest that blinding by the use of encapsulation is not an option since the capsule may impair the initial absorption of the drug and thus reduce the treatment effect (5) . In addition, the drugs that are going to be compared may have different labelling with respect to dosing, contraindications, etc. Furthermore, it may be very dif®cult to get the corresponding placebo tablets of all the different drugs which otherwise would enable us to use the`dummy' technique. So, for practicality and simplicity, an open-labelled, randomised crossover design evaluation of patient preference is therefore suggested when comparing more than two treatment alternatives (1) . If an open design is chosen, it is recommended that the drugs should be presented as they are provided by the pharmacy.
Study population
We have to be sure of the objectives and what we would like to evaluate in a preference study. It is of interest to ask patients to prioritize which features of an acute migraine drug they feel are most important before the study to ascertain whether their prestudy`preferences' match the attributes of the medication they ultimately choose. Some of the patients in the trial may previously have taken different treatments and hence may have higher or lower expectations than those who have not received these treatments previously. In fact recently performed preference study, patients tended to prefer the same treatment as they had taken before participating in this study (3) . It is important to stratify for this in the analysis in order to ®nd out if the latest used treatment affects the patients' choice of preference. In addition to prior use, strati®cation should also be made for prior response or lack of response, prior side-effects or lack of side-effects, etc. Finally, it would be useful to stratifying patients by their expectation score by means of a simple expectation instrument.
In the ®eld of migraine, it is getting more and more dif®cult to recruit triptan naive migraineurs, but in some countries recruitment is still possible within a reasonable timeframe. Is the gain in performing a preference trial in patients naive to triptans worthwhile? Probably not, since recent data suggest that the response pro®le in triptan naive migraineurs is very similar to that obtained in triptan experienced patients (3). More important, in my opinion, is that the study re¯ect the use of the treatments in clinical practice so that data can be extrapolated to most clinical settings. Possibly, it would even be more advantageous to perform patient preference trials in migraineurs who usually respond to triptans and/or ergots (1, 3).
Patient information
The quality of the data outcome in a patient preference trial is very much dependent on how the information about the study is initially communicated to the patients. It is of utmost importance that the information given to the patients is clear and standardized. This would minimize biases and preconceived notions about a particular treatment to come into play and to ensure that the degree of expectation is equal in the study population. Accordingly, we should make sure that the clinical investigators at the outset communicate thè Patient Information' to each individual in an identical way. Ideally, a written version of this information should also be given to the patient.
Single attack or multiple attack design A 2-attack crossover preference study, where patients treat one attack with A and another with B, is easier to evaluate, have fewer protocol violators and minimizes the risk of having dropouts. My concern would be, however, that there is a high risk that the patient's preference will be based on a`no-response event'. This, since most treatments have a low within-individual consistency of response, with only about 40% responding to triptan treatment in 3 out of 3 attacks (6, unpublished observation). We also know from multiple attack studies that about 75% of the migraine population are more likely than the rest (25%) to respond to acute treatment with a triptan (7) . These barriers should, however, be taken care off by an appropriate randomization.
My concern with multiple attack preference study is that multiple attacks on each treatment alternative increase the risk of having dropouts and prolong the time before the study is completed. Another consequence of a multiple attack approach is that the more attacks to be assessed, as the basis of a choice of preference, the fewer drugs can be included in such a study. The memory process may also be impaired by time, so that at the end of the study the patients may not be able to remember the treatments they have taken and how these treatment alternatives were perceived. According to these concerns, a two-attack preference study in which the patients are asked to treat two attacks with each drug would be a good compromise (1) .
Attack frequency does not seem to predict anything with respect to the response of the individual to any of the acute treatment alternatives. We know that the attack frequency of migraineurs who are consulting a physician is about 4 attacks per months. Accordingly, we can allow the patient to have 1±6 attacks per month and to treat 1±2 attacks with each of the treatment alternatives.
Diaries
Historically the triptans have been evaluated and compared on the basis of strictly de®ned clinical ef®cacy parameters and in many ways been arti®cial. Patients have been told to delay treatment until headache intensity becomes moderate or severe and primarily ef®cacy at early time points up to 2±4 h after administration have been looked at. It is recommended that we allow acute treatment at any intensity and that the whole migraine attack is assessed with respect to pain relief, relief of associated symptoms, adverse events, recurrence and the number of doses per attack by the use of diaries (1) . The diaries should be simple and easy for the patients to complete. In addition to that, it is of interest to see what drives the preference for the different drugs (this may differ for different treatments).
Recall period
Asking for most preferred agent is by no means free of bias. The likelihood for an individual, at the end of the trial, to remember all the characteristics of the treatment alternatives tested and consequently to make a reliable and valid choice for preference can be questioned. Thus, one of the important challenges for a preference study is to ensure that patients are capable of making a judgement of preference over what could be a 4±6-month period. One way of doing that is to correlate the patients' experiences of pain relief, relief of associated symptoms, adverse events, recurrence and the number of doses per attack with their ®nal decision about which treatment they prefer to continue taking (3) .
Given that the patients have been correctly informed on the objectives of the study at the very beginning, the patients should not be allowed to look back into their diaries when making the ®nal ranking. To try and overcome any possible period/sequence effects, however, one could also allow the patient to look back at the data he/she recorded for earlier treatments and afterward make a second judgement. In order to evaluate the effect of looking back, two identical evaluation pages can be used. The former is ®lled in based on memory and the latter is ®lled in after the migraineur has been able to look back at his/her previously completed diaries. This model was used in a recently performed randomised, multicentre, open-label, 5-way cross-over, preference study performed in ®ve countries, several triptans were analysed in both triptan-naõ Ève and triptan-experienced patients who experienced mild, moderate, and severe migraine attacks (3) . It was demonstrated that patient perception of subjective overall preference for a triptan was not different when assessed with and without access to their headache diaries (3) .
Each patient would also be asked to rank each drug on a 1±5 (1±10)-point scale and indicate the drug he or she preferred the most, without looking back in their diaries. Alternatively, each treatment alternative should be rated after each attack by experience but eventually the patient is asked to make a choice between the tested drugs without looking back in their diaries. This will give`n onbiased' rankings and implied preference. Thereafter the patient has the option to review their diaries while completing the modi®ed second page of the assessment where they once again are asked to rank each drug on a 1±5 (1±10) point scale and indicate their ®rst preference. The reason to chose the ranking option rather than just asking for their ®rst preference is that the former approach gives you an estimate of their strength of preference. It is, however, important that the scale should be balanced with equal positive and negative options around the neutral point. Recent preference studies demonstrate that several migraineurs rated the different triptans very similarly (3-4-3, 4-4-4, 4-3-3, etc.) but despite these ambiguous responses, each patient came up with one triptan of preference (1, 3) .
Dosing
The easiest way is to compare the generally recommended doses. Data from a recently performed patient preference study using open-labelled, randomised crossover design demonstrates that patients tend to prefer the higher dose if more than one dose of the drug is evaluated (3). This despite the fact that the pain-free responses at 2 h for the two doses studied were very similar. Another option would be to allow each patient to optimize ef®cacy via dose titration. This is more complicated but would provide data on patient preference under conditions where treatment effects are similar. This would provide a more equal playing ®eld of ef®cacy and may lead to preference choices based on other issues (i.e. more reliable, better tolerability, low recurrence rate, etc).
Migraine prophylactic treatment can be continued but not changed during this type of preference trial. Use of rescue medication may affect patient preference but may also be dif®cult to avoid for ethical considerations.
Commentary
In a recent issue of Cephalalgia, Pascual et al. (8) report the results of an open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in migraine patients. One hundred patients with migraine, diagnosed according to IHS criteria, were recruited consecutively from patients attending two Spanish neurology clinics. Eligible patients were those who either currently were using a triptan for their migraine attacks or those who, after their visit, were recommended to use a triptan for symptomatic treatment of their migraine attacks. The two, at the time in Spain, only available oral formulations of triptans, sumatriptan, 50 mg tablets, and of zolmitriptan, 2.5 mg tablets, were prescribed to eligible migraineurs. The price in Spain for these two triptans is the same, but the patient only pays 40% of the total cost of the medication.
Patients were informed that sumatriptan 50 mg and zolmitriptan 2.5 mg could be very similar with respect to ef®cacy and tolerability, but that they, in spite of this, may have preference for one in front of the other. In addition, that they could use up to two tablets in order to relieve the symptoms of their migraine attack. Patients were asked to treat at least three attacks with each medication and to record how many tablets they used per attack. Finally to return to the neurology clinics in order to ®ll in a preference questionnaire. The preference questionnaire included simple questions on the number of tablets of each triptan used as the initial treatment for their migraine attacks; whether they preferred sumatriptan, zolmitriptan or both; and, if they had expressed a preference, their reasons for this. A number of possible reasons for preference (i.e. faster onset of action (speed of onset), longer duration of the effect, better tolerability and lower cost) were given in the questionnaire but they could also ®ll in other reasons.
Ninety-four migraine patients completed the study, 50 (53%) of these were prior to the study using sumatriptan for acute treatment of their migraine attacks, 31 (33%) were using zolmitriptan. Both these groups were naive for the other triptan. The remaining 13 (14%) had no experience of either of the triptans before entering this study. Signi®cantly more migraine patients (67 out of 94 patients=67%) obtained initial headache relief on a single tablet of zolmitriptan 2.5 mg compared to a single tablet of sumatriptan 50 mg (36 out of 94 patients=39%).
In total, 27 (29%) of the migraine patients preferred sumatriptan for acute treatment of their migraine attacks, 42 (44%) zolmitriptan and the rest 25 (27%) did not indicate any subjective preference (8) . The most frequently reported reasons for preference among those 69 patients who had indicated preference for either of the two triptans were a faster onset of action (speed of onset) (73%), a longer duration of the effects (39%) and fewer adverse events (35%). The allocation of future preference for each of the three groups (sumatriptan users, zolmitriptan users and triptan naive) was as follows (J. Pascual personal communication):
Suma (n=50)=Suma (n=21, 42%), Zolmi (n=24, 48%) and No preference (n=5, 10%) Zolmi (n=31)=Suma (n=3, 10%), Zolmi (n=14, 45%) and No preference (n=14, 45%) Naive (n=13)=Suma (n=3, 23%), Zolmi (n=4, 31%) and No preference (n=6, 46%).
Very much in accordance with what has been outlined above this patient preference study by Pascual et al. (8) used an open-label, crossover design in order to re¯ect the situation in clinical practice. For the same reason, the evaluation was performed in both triptan experienced and triptan naive migraineurs. The two triptans were presented as they are provided by the pharmacy and the generally recommended doses were used. The information to the migraine patients at the outset was given in an appropriate and identical way in order to minimize biases and preconceived notions. The patient's choice of preference was obtained after they had treated three migraine attacks with each of the triptans. Despite of this the study could be completed with only a few dropouts. The diaries used were simple and easy for the patients to complete.
So, which are the potential drawbacks and confounding factors in this particular study? The study was neither randomised nor blinded but, most likely, this does not explain the differences in patient's preference that were obtained. Prior to the study 53% of the migraine patients were currently using sumatriptan for acute treatment of their migraine attacks and 33% were using zolmitriptan. Based on ®ndings in a recently performed randomised, multicentre, open-label, 5-way cross-over, preference study performed with several triptans, one would expect most patients to prefer the same treatment as they had taken before participating in this study (3) . On the contrary, more (48%) of the prior sumatriptan users indicated after having completed the study that they preferred zolmitriptan 2.5 mg tablets over sumatriptan 50 mg tablets than those (42%) who preferred to use sumatriptan also in the future. In this group of prior sumatriptan users only few (10%) had no preference. In both the group of prior zolmitriptan users and the group of triptan naõ Ève the percentages that indicated no preference were much higher (about 45%). So, in the absence of any value on the strength of preference one could also interpret the data that both triptans are very similarly perceived. Signi®cantly more migraine patients obtained initial headache relief on a single tablet of zolmitriptan 2.5 mg compared to a single tablet of sumatriptan 50 mg. It is possible that this have had an impact on their choice of preference. As pointed out by the authors, however, the difference in patient preference between the two triptans (15%) should be interpreted with caution, since the 95% C.I. overlap and there could be an order of treatment effect. In addition, we cannot rule out the impact of having carry-over effects from one triptan to the other in this type of crossover study and/or within-patient variability when testing each of the two drugs. Furthermore, no attempts were made to estimate the strength of preference.
It is clear that patient preference data can provide important information to supplement that obtained from traditional ef®cacy measures and should be considered in tailoring migraine therapy to the needs of the individual patient. It is not very likely, however, that we will be able to con®dently match a triptan to an individual patient based on their a priori preferences of what they would like in a drug without doing a mini-preference trial in each patient. In any case, we have to learn more about how to obtain data on patients' preference for migraine therapy that are more reliable but still closely approximate normal clinical use of medications.
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